Literature DB >> 32598931

Exosomal release of microRNA-454 by breast cancer cells sustains biological properties of cancer stem cells via the PRRT2/Wnt axis in ovarian cancer.

Ling Wang1, Miao He2, Li Fu1, Yuemei Jin3.   

Abstract

AIMS: Cancer-derived exosomes carrying tumor-derived molecules such as miRNAs and proteins related to various phenotypes have been detected in both the bloodstream and other biofluids of patients with different cancers. Thus, our main purpose here was to determine the role of the exosomal microRNA-454 (miR-454) derived by MDA-MB-231 in self-renewal of cancer stem cells (CSCs) in ovarian cancer (OC).
MATERIALS AND METHODS: Extraction of MDA-MB-231 cells-derived exosomes (231-derived exosomes) was conducted to treat CD44+/CD133+ SKOV3 and CoC1 cells to observe cell growth and stemness. Next, the differentially expressed miRNAs in SKOV3 cells after exosome treatment were filtered using microarray analysis. Subsequently, the cell viability was detected after reducing the exosomal miR-454 and the addition of a Wnt pathway inhibitor C59. Finally, the pro-tumorigenic function of exosomes on OC cells in vivo was investigated. KEY
FINDINGS: After co-culture with 231-derived exosomes, the stemness of CSCs were promoted. Subsequently, the reduction of exosomal miR-454 weakened the roles of exosomes on cell stemness. Proline-rich transmembrane protein 2 (PRRT2) was substantiated as a target gene of miR-454 in SKOV3 and CoC1 cells. C59 reversed the repressive role of exosomes in stemness of CSCs. When being evaluated in a mouse model, exosomal miR-454 led to an efficacious effect in suppressing the tumor weight and volume in vivo. SIGNIFICANCE: Altogether, 231-derived exosomes carrying miR-454 disrupted the Wnt pathway by targeting PRRT2, thereby promoting CSC stemness in vitro and OC cell growth in vivo.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Exosomes; PRRT2; The Wnt pathway; microRNA-454

Mesh:

Substances:

Year:  2020        PMID: 32598931     DOI: 10.1016/j.lfs.2020.118024

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Tumor Suppressor 4.1N/EPB41L1 is Epigenetic Silenced by Promoter Methylation and MiR-454-3p in NSCLC.

Authors:  Qin Yang; Lin Zhu; Mao Ye; Bin Zhang; Peihe Zhan; Hui Li; Wen Zou; Jing Liu
Journal:  Front Genet       Date:  2022-06-20       Impact factor: 4.772

Review 2.  Characteristics of Extracellular Vesicles and Preclinical Testing Considerations Prior to Clinical Applications.

Authors:  Min Heui Yoo; A-Ram Lee; Kyoung-Sik Moon
Journal:  Biomedicines       Date:  2022-04-07

Review 3.  Exosomes and Cancer Stem Cells in Cancer Immunity: Current Reports and Future Directions.

Authors:  Na-Kyeong Lee; Vinoth Kumar Kothandan; Sangeetha Kothandan; Youngro Byun; Seung-Rim Hwang
Journal:  Vaccines (Basel)       Date:  2021-05-01

Review 4.  Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion.

Authors:  Wanjia Tian; Ningjing Lei; Junying Zhou; Mengyu Chen; Ruixia Guo; Bo Qin; Yong Li; Lei Chang
Journal:  Cell Death Dis       Date:  2022-01-18       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.